Sjöblom, A.; Stenman, U.-H.; Hagström, J.; Jouhi, L.; Haglund, C.; Syrjänen, S.; Mattila, P.; Mäkitie, A.; Carpén, T.
Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status. Cancers 2021, 13, 2811.
https://doi.org/10.3390/cancers13112811
AMA Style
Sjöblom A, Stenman U-H, Hagström J, Jouhi L, Haglund C, Syrjänen S, Mattila P, Mäkitie A, Carpén T.
Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status. Cancers. 2021; 13(11):2811.
https://doi.org/10.3390/cancers13112811
Chicago/Turabian Style
Sjöblom, Anni, Ulf-Håkan Stenman, Jaana Hagström, Lauri Jouhi, Caj Haglund, Stina Syrjänen, Petri Mattila, Antti Mäkitie, and Timo Carpén.
2021. "Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status" Cancers 13, no. 11: 2811.
https://doi.org/10.3390/cancers13112811
APA Style
Sjöblom, A., Stenman, U.-H., Hagström, J., Jouhi, L., Haglund, C., Syrjänen, S., Mattila, P., Mäkitie, A., & Carpén, T.
(2021). Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status. Cancers, 13(11), 2811.
https://doi.org/10.3390/cancers13112811